Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
137M
-
Shares change
-
+4.07M
-
Total reported value, excl. options
-
$438M
-
Value change
-
+$24.4M
-
Put/Call ratio
-
0.17
-
Number of buys
-
59
-
Number of sells
-
-37
-
Price
-
$3.19
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q3 2025
121 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q3 2025.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 137M shares
of 166M outstanding shares and own 82.98% of the company stock.
Largest 10 shareholders include VR ADVISER, LLC (15.6M shares), FMR LLC (15.4M shares), TANG CAPITAL MANAGEMENT LLC (11.1M shares), PERCEPTIVE ADVISORS LLC (9.68M shares), VANGUARD GROUP INC (8.95M shares), ORBIMED ADVISORS LLC (8.46M shares), Commodore Capital LP (7.69M shares), BAKER BROS. ADVISORS LP (4.25M shares), Point72 Asset Management, L.P. (4.07M shares), and ADAR1 Capital Management, LLC (4.05M shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.